Doctors safely added the vitamin D drug paricalcitol to chemotherapy in a small pancreatic cancer trial
Dana-Farber researchers safely combined paricalcitol, an approved vitamin D drug, with chemotherapy in a small trial in metastatic pancreatic cancer. Its strongest survival signal came in tumours rich in the vitamin D receptor, a possible way to choose patients that a larger trial still has to test.
Reality
- Evidence45
- Adoption
- Not scored
- Hype gap+40
- Incentives65
- Confidence50
buildOne report1 publisher Microsoft's Quine closes the loop between a biology model and the wet lab
Microsoft says its Quine system narrowed thousands of compounds to a pancreatic cancer shortlist in one weekend. For research-AI teams, the part to study is the harness that sends lab results back into the next question, and nobody has yet measured its value across cycles.
Reality
- Evidence35
- Adoption
- Not scored
- Hype gap+30
- Incentives65
- Confidence40
The FDA cleared daraxonrasib on Aug. 26 for patients whose chemotherapy has already failed. The median gain is 6.5 months, and the price has not been disclosed.
Perspective Coverage
3 publishers
- Builder
- Builder 27%
- Operator
- Operator 58%
- Investor
- Investor 15%
Reality
- Evidence60
- Adoption
- Not scored
- Hype gap+20
- Incentives
- Not scored
- Confidence65
Clinicians answer the AI cure-for-cancer claim with more than 100 brain tumour types
A Melbourne oncologist told the Guardian she doubts a cure for all cancer inside 10 years, and the clinicians who said so expect the real gains in diagnostics, pathology and treatment selection. Those are steps a budget can be written against.
Reality
- Evidence62
- Adoption30
- Hype gap+58
- Incentives55
- Confidence64
A City of Hope team reports catching stage 1 and 2 pancreatic cancer from a three-marker blood score. The trial does not settle what a positive means in the high-risk groups a screening programme would enrol first.
Reality
- Evidence57
- Adoption8
- Hype gap+33
- Incentives63
- Confidence61
Rasonque's approval closed its compassionate-use program before insurers were ready to pay
Revolution Medicines' expanded access program for Rasonque closed immediately on FDA approval, leaving patients still mid-application to wait on insurers whose paperwork moves slower than metastatic pancreatic cancer.
Reality
- Evidence62
- Adoption45
- Hype gap+12
- Incentives55
- Confidence60